ND_L02_s0201



NAME OF DRUG : ND_L02_s0201

ALSO KNOWN AS : ND_L02_s0201

LABORATORY : NITTODENKO

STATUS AND ADVANCEMENT

Type of drug : (SERPINH1) (Hsp47)

Clinical trials advancement : Ongoing Phase 1

Estimated time to market : 128 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

RECENT NEWS ON ND_L02_s0201

SOME PUBLICATIONS RELATED WITH ND_L02_s0201

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH ND_L02_s0201


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE